Incyte completes $1.25B acquisition of Vega Therapeutics, adds Phase 3 VGA039 for VWD

Incyte completed the $1.25 billion acquisition of Vega Therapeutics, adding VGA039, a Phase 3 investigational monoclonal antibody for von Willebrand disease.

Key Highlights:

• Acquisition closed July 6, 2026; Incyte acquired all outstanding shares of Vega Therapeutics for $1.25B upfront.
• VGA039, a novel monoclonal antibody in Phase 3 (VIVID-6) for VWD, is added to Incyte’s hematology portfolio.
• Star Therapeutics may receive up to $750M in additional payments upon achievement of sales milestones.
• Transaction will be recorded as a one-time R&D expense in Q3 and full-year 2026 GAAP and non-GAAP results.
• VGA039 has Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations from the FDA.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.